Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Moderna, Inc.: Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Accesswire) +++ MODERNA Aktie +3,19%

REGENERON Aktie

 >REGENERON Aktienkurs 
693.2 EUR    -0.9%    (TradegateBSX)
Ask: 695.8 EUR / 9 Stück
Bid: 690.7 EUR / 9 Stück
Tagesumsatz: 162 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -2,8%
1 Monat: +20,3%
3 Monate: +28,4%
6 Monate: +7,5%
1 Jahr: +39,5%
laufendes Jahr: +5,5%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..
Marktkapitalisierung:  73058.06 Mio. EUR
Unternehmenswert:  68423.94 Mio. EUR
Umsatz:  13305.5 Mio. EUR
EBITDA:  4027.61 Mio. EUR
Nettogewinn:  3707.54 Mio. EUR
Gewinn je Aktie:  35.89 EUR
Schulden:  2318.21 Mio. EUR
Liquide Mittel:  2112.13 Mio. EUR
Operativer Cashflow:  4009.54 Mio. EUR
Bargeldquote:  1.45
Umsatzwachstum:  12.73%
Gewinnwachstum:  0.14%
Dividende je Aktie:  3.18 EUR
Dividendenrendite:  0.44%
Dividendenschätzung:  0.46%
Div. Historie:  18.08.26 - 0.80548596€
20.05.26 - 0.808306€
>weitere anzeigen...
Insiderhandel:  2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 823.614 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  27.08.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.14 Mio. St.
Frei handelbar: 97.99%
Leerverk. Aktien: 2.37%
Rückkaufquote: 2.98%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 1.73%
Bewertung:
KGV: 20.3
KGV lG: 15.47
KUV: 5.67
KBV: 2.68
PEG-Ratio: 10.51
EV/EBITDA: 16.99
Rentabilität:
Bruttomarge: 81.46%
Gewinnmarge: 27.86%
Operative Marge: 26.87%
Managementeffizenz:
Gesamtkaprendite: 10.83%
Eigenkaprendite: 14.04%
>REGENERON Peer Group
 
27.08.26 - 22:09
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......
27.08.26 - 16:12
 REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline (PR Newswire)
 
Control-person liability allegations focus on Regeneron executives' alleged authority over public clinical-trial statements and SEC disclosures as REGN shares fell $102.09 from the Class Period high. NEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt notifies investors in Regeneron......
27.08.26 - 00:18
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
26.08.26 - 16:09
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky (PR Newswire)
 
This promise-vs-reality notice focuses on allegations that Regeneron promoted Phase I Fianlimab-Libtayo results and practice-changing expectations while the Phase III study allegedly faced heightened statistical and clinical failure risk. NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Levi &......
25.08.26 - 13:15
 Veeva Vault CRM Selected by Regeneron (PR Newswire)
 
Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron......
24.08.26 - 18:39
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
21.08.26 - 10:42
 Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
 
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
20.08.26 - 19:06
 REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt (PR Newswire)
 
This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact on Regeneron's pipeline and future growth expectations. NEW YORK, Aug. 20, 2026......
20.08.26 - 18:15
 Regeneron Secures FDA Approval for Rare Genetic Disorder Drug (Zacks)
 
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups....
20.08.26 - 15:30
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
20.08.26 - 04:27
 REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses (PR Newswire)
 
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the......
19.08.26 - 19:54
 Regeneron wins FDA nod for rare bone disorder therapy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
19.08.26 - 19:18
 REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky (PR Newswire)
 
Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Levi & Korsinsky,......
18.08.26 - 16:12
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm (PR Newswire)
 
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead......
18.08.26 - 12:27
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
17.08.26 - 09:33
 Bayer-Partner Regeneron überrascht – jetzt kaufen? (Der Aktionaer)
 
In den vergangenen Wochen hat eine ganze Reihe von Pharma- und Biotech-Unternehmen die Zahlen für das zurückliegende Quartal vorgelegt. DER AKTIONÄR verrät, wer am besten abgeschnitten hat und wie Regeneron nach dem Rücksetzer im Mai nun dasteht und ob man bei der Aktie jetzt zugreifen sollte....
16.08.26 - 21:36
 XETR: DIVIDEND/INTEREST INFORMATION - 18.08.2026 - US75886F1075 (XETRA)
 
Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 17.08.2026 und ex Dividende/Zinsen am 18.08.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 17.08.2026 and its ex-dividend/interest day on 18.08.2026...
14.08.26 - 21:36
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman (PR Newswire)
 
SAN FRANCISCO, Aug. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
13.08.26 - 18:54
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt (PR Newswire)
 
This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses. NEW YORK, Aug.......
13.08.26 - 16:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Aus einem Weisen wird man nicht klug. - Elazar Benyoetz
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!